Current Trends in Migraine Prophylaxis
Author:
- 9 April 2007
- journal article
- review article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 47 (s1) , S52-S57
Abstract
A variety of drugs from diverse pharmacological classes are in use for migraine prevention. Traditionally, they have been discovered by serendipity. Examples include β‐adrenergic blockers, anticonvulsants, tricyclic antidepressants, and serotonin receptor antagonists. The mechanisms of action of migraine preventive drugs are multiple but it is postulated that they converge on two targets: (1) inhibition of cortical excitation; (2) restoring nociceptive dysmodulation. The antiepileptic drugs (e.g., topiramate, valproate, gabapentin), calcium channel blockers such as verapamil, and inhibitors of cortical spreading depression are some examples of drugs that reduce neuronal hyperexcitability. On the other hand, modulators of the serotonergic and adrenergic systems and cholinergic enhancing drugs may restore descending nociceptive inhibition and play a role in migraine prevention. To date, Level 1 evidence and clinical experience favor the use of the antidepressant amitriptyline, the anticonvulsants divalproex and topiramate, and the β‐adrenergic blockers propranolol, timolol and metoprolol as first line migraine preventive drugs. The evidence for others (e.g., verapamil) is not as strong. Migraine preventive drugs have varying degrees of adverse effects, some of which could be limiting, and their efficacy should balanced with their risks of adverse effects, patients' expectations and desires, and compliance. It is hoped that future migraine preventive drugs target migraine mechanisms more specifically, which could well enhance the therapeutic index.Keywords
This publication has 36 references indexed in Scilit:
- Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA studyBrain, 2005
- Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- Anticonvulsants and the Relief of Chronic Pain: Pregabalin and Gabapentin as α2δ Ligands at Voltage-Gated Calcium ChannelsThe Journal of Clinical Psychiatry, 2004
- The First Placebo-Controlled Trial of a Special Butterbur Root Extract for the Prevention of Migraine: Reanalysis of Efficacy CriteriaEuropean Neurology, 2004
- Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cellsEuropean Journal of Pharmacology, 2003
- Spreading Depression: Imaging and Blockade in the Rat Neocortical Brain SliceJournal of Neurophysiology, 2002
- Handbook of HeadacheHeadache: The Journal of Head and Face Pain, 2002
- Migraine: imaging the auraCurrent Opinion in Neurology, 2000
- 239 Migraine prophylaxis by brain cholinesterase inhibitorsInternational Journal of Psychophysiology, 1998